Status | Study |
Completed |
Study Name: Telotristat Etiprate for Carcinoid Syndrome Therapy Condition: Carcinoid Syndrome Date: 2014-02-12 Interventions: Drug: Telotristat etiprate tablets (250 mg) |
Active, not recruiting |
Study Name: Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Condition: Carcinoid Syndrome Date: 2013-12-31 Interventions: Drug: Telotristat etiprate tablets (250 mg) Other Name: LX1606 |
Completed |
Study Name: An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males Condition: Carcinoid Syndrome Date: 2013-08-27 Interventions: Drug: 500 mg [14C]-LX1606 500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of |
Terminated |
Study Name: P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome Condition: Neuroendocrine Carcinoma Date: 2013-06-21 Interventions: Drug: Octreotide LAR Octreotide LAR as outlined in Treatment Arm. |
Completed |
Study Name: TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Condition: Carcinoid Syndrome Date: 2012-08-30 Interventions: Drug: Telotristat etiprate tablets (250 mg) |
Completed |
Study Name: Effects of Serotonin Excess on Bone in Carcinoid Syndrome Condition: Carcinoid Syndrome Date: 2011-08-26 |
Completed |
Study Name: A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea Condition: Neuroendocrine Tumors Carcinoid Syndrome Date: 2010-10-20 |
Withdrawn |
Study Name: Study of Panitumumab in the Treatment of Carcinoid Syndrome Condition: Carcinoid Syndrome Date: 2010-07-28 Interventions: Drug: Panitumumab Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of stu |
Completed |
Study Name: Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Condition: Symptoms of Carcinoid Syndrome Date: 2010-04-12 Interventions: Drug: Low Dose LX1606 - Day 1 (start) |
Terminated |
Study Name: Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Condition: Carcinoid Syndrome Date: 2009-11-24 Interventions: Drug: BIM 23A760 BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection |